Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets of $6.88M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets increased by 44.5% year-over-year, from $4.76M to $6.88M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets has grown at a 139.6% compound annual growth rate (CAGR), from $87K to $6.88M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.